These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 16237736)
21. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma. Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D J BUON; 2007; 12(1):99-104. PubMed ID: 17436409 [TBL] [Abstract][Full Text] [Related]
22. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Jones MB; Krutzsch H; Shu H; Zhao Y; Liotta LA; Kohn EC; Petricoin EF Proteomics; 2002 Jan; 2(1):76-84. PubMed ID: 11788994 [TBL] [Abstract][Full Text] [Related]
23. Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients. Høgdall E; Fung ET; Christensen IJ; Yip C; Nedergaard L; Engelholm SA; Risum S; Petri AL; Lundvall L; Lomas L; Høgdall C Proteomics Clin Appl; 2010 Dec; 4(12):940-52. PubMed ID: 21137034 [TBL] [Abstract][Full Text] [Related]
24. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Simon I; Zhuo S; Corral L; Diamandis EP; Sarno MJ; Wolfert RL; Kim NW Cancer Res; 2006 Feb; 66(3):1570-5. PubMed ID: 16452214 [TBL] [Abstract][Full Text] [Related]
25. Multiplexed bead-based immunoassay of four serum biomarkers for diagnosis of ovarian cancer. Kim YW; Bae SM; Kim IW; Liu HB; Bang HJ; Chaturvedi PK; Battogtokh G; Lim H; Ahn WS Oncol Rep; 2012 Aug; 28(2):585-91. PubMed ID: 22641176 [TBL] [Abstract][Full Text] [Related]
26. A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer. Høgdall C; Fung ET; Christensen IJ; Nedergaard L; Engelholm SA; Petri AL; Risum S; Lundvall L; Yip C; Pedersen AT; Hartwell D; Lomas L; Høgdall EV Gynecol Oncol; 2011 Nov; 123(2):308-13. PubMed ID: 21855971 [TBL] [Abstract][Full Text] [Related]
27. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Ehmann M; Felix K; Hartmann D; Schnölzer M; Nees M; Vorderwülbecke S; Bogumil R; Büchler MW; Friess H Pancreas; 2007 Mar; 34(2):205-14. PubMed ID: 17312459 [TBL] [Abstract][Full Text] [Related]
28. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture. Scarlett CJ; Saxby AJ; Nielsen A; Bell C; Samra JS; Hugh T; Baxter RC; Smith RC Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699 [TBL] [Abstract][Full Text] [Related]
29. Identification of ovarian cancer-associated proteins in symptomatic women: A novel method for semi-quantitative plasma proteomics. Shield-Artin KL; Bailey MJ; Oliva K; Liovic AK; Barker G; Dellios NL; Reisman S; Ayhan M; Rice GE Proteomics Clin Appl; 2012 Apr; 6(3-4):170-81. PubMed ID: 22532453 [TBL] [Abstract][Full Text] [Related]
31. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277 [TBL] [Abstract][Full Text] [Related]
32. [Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors]. Liu YN; Ye X; Cheng HY; Cheng YX; Fu TY; Chen J; Chang XH; Cui H Zhonghua Fu Chan Ke Za Zhi; 2010 May; 45(5):363-6. PubMed ID: 20646446 [TBL] [Abstract][Full Text] [Related]
33. Discovery and application of protein biomarkers for ovarian cancer. Gagnon A; Ye B Curr Opin Obstet Gynecol; 2008 Feb; 20(1):9-13. PubMed ID: 18196999 [TBL] [Abstract][Full Text] [Related]
34. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Moore RG; Brown AK; Miller MC; Skates S; Allard WJ; Verch T; Steinhoff M; Messerlian G; DiSilvestro P; Granai CO; Bast RC Gynecol Oncol; 2008 Feb; 108(2):402-8. PubMed ID: 18061248 [TBL] [Abstract][Full Text] [Related]
35. Proteomic studies of early-stage and advanced ovarian cancer patients. Wang J; Zhang X; Ge X; Guo H; Xiong G; Zhu Y Gynecol Oncol; 2008 Oct; 111(1):111-9. PubMed ID: 18703221 [TBL] [Abstract][Full Text] [Related]
36. Identification and confirmation of differentially expressed fucosylated glycoproteins in the serum of ovarian cancer patients using a lectin array and LC-MS/MS. Wu J; Xie X; Liu Y; He J; Benitez R; Buckanovich RJ; Lubman DM J Proteome Res; 2012 Sep; 11(9):4541-52. PubMed ID: 22827608 [TBL] [Abstract][Full Text] [Related]
37. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors. Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323 [TBL] [Abstract][Full Text] [Related]
38. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer. Camlica H; Duranyildiz D; Tas F; Yasasever V Am J Clin Oncol; 2008 Dec; 31(6):585-8. PubMed ID: 19060592 [TBL] [Abstract][Full Text] [Related]
39. Mass profiling-directed isolation and identification of a stage-specific serologic protein biomarker of advanced prostate cancer. Lam YW; Mobley JA; Evans JE; Carmody JF; Ho SM Proteomics; 2005 Jul; 5(11):2927-38. PubMed ID: 15952230 [TBL] [Abstract][Full Text] [Related]
40. [Identification of serum biomarkers for ovarian cancer using protein chips and time of flight mass spectrometry technology]. Wang Q; Li L; Li DR; Zhang W; Wei X; Zhang JQ; Tang Y Zhonghua Fu Chan Ke Za Zhi; 2006 Aug; 41(8):544-8. PubMed ID: 17083841 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]